Pharmacodynamics and pharmacokinetics of clentiazem and diltiazem in closed-chest anesthetized dogs
β Scribed by Sylvie Giasson; Denis Garceau; Walid Homsy; Louis Dumont
- Publisher
- Springer US
- Year
- 1995
- Tongue
- English
- Weight
- 828 KB
- Volume
- 9
- Category
- Article
- ISSN
- 0920-3206
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The in vivo performance of multiparticulate sustained-release diltiazem preparations [HER-SR(A,B,C)] coated with water-insoluble polymer (ethylcellulose), to control the in vitro dissolution rate, was evaluated in dogs. With a decrease in dissolution rate, HER-SR maintained sustained-release charact
CardizemOSR and Bi-TildiemO were both approved in their respective countries on the basis of clinical trials demonstrating efficacy and safety in the treatment of angina pectoris. In this cross-over randomized study, we assessed whether these two sustained-release formulations of diltiazem have equi
We evaluated the relationship between the cardiovascular effects of clentiazem (TA-3090), a new 1,5-benzothiazepine calcium antagonist with high lipophilicity, and both its plasma and myocardial concentrations. Anesthetized, open-chest dogs, instrumented for hemodynamic data recording and blood samp
## Abstract In order to determine the potential pharmacokinetic drug interaction between ranitidine and diltiazem (DTZ), each of ten male beagle dogs, age 2Β·7β4Β·0 years, weight 13β16 kg, received a single oral dose of sustained release DTZ with and without previous multiple oral doses of ranitidine